Anti-anxiety traditional Chinese medicine charcoal medicine

Abstract

The invention relates to the field of medicine, in particular to application of chrysanthemum charcoal in preparation of an anti-anxiety drug. Animal experiments find that chrysanthemum charcoal has an improvement effect on anxiety-like behaviors and has activity of regulating related neurotransmitter and hormone levels.

Description

Technical Field

[0001] The invention relates to the field of medicine, and in particular to application of chrysanthemum charcoal in preparing antianxiety drugs. Background Art

[0002] Anxiety is a common, psychological, cyclical, rhythmic emotional disease with a high incidence and recurrence rate. If it is not given enough attention and actively treated, it may cause serious physical and mental effects and even endanger the quality of life. Currently, commonly used clinical treatments include anti-anxiety drugs, psychotherapy, relaxation training and lifestyle adjustments, but these cannot effectively control its high recurrence rate, and there are also certain side effects or treatment difficulties. Therefore, finding a safe, efficient and affordable drug has become an urgent need in current clinical practice.

[0003] Chrysanthemum is the dried inflorescence of Chrysanthemum morifolium Ramat. of the Asteraceae family. Chrysanthemum charcoal is a processed Chinese medicine that can be used clinically for mild hemoptysis. Summary of the invention

[0004] In view of this, the object of the present invention is to provide a safe and inexpensive Chinese herbal charcoal medicine with antianxiety effect, so as to be used in combination or alone in clinical practice.

[0005] Specifically, the present invention is achieved by using chrysanthemum charcoal in the preparation of antianxiety drugs, and the preparation of chrysanthemum charcoal comprises the following steps:

[0006] Take chrysanthemum medicine and put it into a crucible, wrap the crucible mouth with tin foil to seal it, cover the crucible with a lid and put it into a muffle furnace and set a certain temperature for firing.

[0007] The invention provides a new use of chrysanthemum charcoal, which mainly relieves anxiety-like behaviors by regulating the activities of corresponding hormones and neurotransmitters. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] Figure 1 .Effects of chrysanthemum charcoal on mCPP-treated mice in the open field test. Figure 1 (A) Average heat map of mouse activity in the open field test. Figure 1 (B) Path diagram of mouse activities in the open field test. Figure 1 (C) Proportion of time spent in the central area relative to the total area (%). Figure 1 (D) The percentage of the number of times entering the central area to the total area (%). Figure 1 (E) Total distance traveled (cm).

[0009] Figure 2 .Effect of chrysanthemum charcoal on mCPP-treated mice in the elevated maze test. Figure 2 (A) Average heat map of mouse activity during the elevated maze test. Figure 2 (B) Path diagram of mouse activities in the elevated maze test. Figure 2 (C) Proportion of time spent in the open arms relative to the total arms (%). Figure 2 (D) The percentage (%) of the number of entries into the open arm to the number of entries into the total arms. Figure 2 (E) Total distance traveled (cm).

[0010] Figure 3 .Effects of chrysanthemum charcoal on hormones and neurotransmitters in the hypothalamus-pituitary-adrenal axis. Figure 3 (A) Corticotropin-releasing hormone (CRH) in serum, Figure 3 (B) adrenocortical hormone (ACTH), and Figure 3 (C) Corticosterone (CORT) concentration. Figure 3 (D) 5-hydroxytryptamine (5-HT) in brain tissue homogenate, Figure 3 (E) Dopamine (DA), Figure 3 (F) Norepinephrine (NE), Figure 3 (G) glutamate (Glu), and Figure 3 (H) Gamma-aminobutyric acid (GABA) concentration. DETAILED DESCRIPTION

[0011] The technical solution of the present invention will be clearly and completely described below in conjunction with specific embodiments, but the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0012] Example 1: A method for preparing chrysanthemum charcoal (calcined), comprising the following steps:

[0013] Put chrysanthemum into the crucible, cover the crucible mouth with aluminum foil, cover the lid tightly, put it in the muffle furnace, and carbonize it at 350℃ for 1h. Then open the door of the muffle furnace after the temperature drops to room temperature, and take out the crucible. The product in the crucible is chrysanthemum charcoal, which is completely carbonized without ash. Compared with the process of preparing chrysanthemum charcoal by frying, this method has clear preparation parameters and good reproducibility.

[0014] Example 2: Study on the antianxiety effect of chrysanthemum charcoal

[0015] 1. Experimental Animals

[0016] This experiment used SPF male ICR mice (weight 20.0-22.0 g) as experimental subjects. All mice were raised in a standardized environment, with free access to food and water, an ambient temperature of (25.0±1.0)°C, a relative humidity of 55-65%, and a circadian rhythm of 12 hours of light during the day and night.

[0017] 2. Drug administration, modeling and sampling of experimental animals

[0018] A total of 48 male ICR mice were randomly divided into six groups. After a three-day adaptation period, the intervention regimen for each group began as follows: control group, model group and positive group (normal saline 10mL / kg, gavage), high-dose pretreatment group (0.1mg / kg, gavage), medium-dose pretreatment group (0.05mg / kg, gavage), and low-dose pretreatment group (0.025mg / kg, gavage). The intervention was carried out for 14 consecutive days.

[0019] The open field test was performed on the 15th day, and the elevated maze test was performed on the 16th day. Two hours before the start of the experiment, the mice were brought to the experimental site for adaptation. One hour before the start of the experiment, each group was intervened as follows: control group (normal saline 10mL / kg, gavage), model group (normal saline 10mL / kg, gavage), positive group (diazepam, 2mg / kg, gavage), high-dose pretreatment group (0.1mg / kg, gavage), medium-dose pretreatment group (0.05mg / kg, gavage), and low-dose pretreatment group (0.025mg / kg, gavage). The anxiety model was established 30 minutes before the start of the experiment using the following scheme: control group (normal saline 10mL / kg, intraperitoneal injection), other groups (meta-chlorophenylpiperazine 2mg / kg, intraperitoneal injection)

[0020] Samples were collected on day 17. The intervention was performed one hour after the mice arrived at the experimental site. The anxiety model was established 30 minutes later. After another 30 minutes, blood samples and brain tissues were systematically collected from the mice. The intervention method and the anxiety model were established in the same way as during the behavioral experiment.

[0021] After collecting samples, the concentrations of hypothalamic-pituitary-adrenal axis hormones in serum and neurotransmitter concentrations in brain tissue were measured using enzyme-linked immunosorbent assay (ELISA). Video analysis software was used to observe and extract video data of the mouse behavior experiment.

[0022] 3. Effects of Chrysanthemum Charcoal on Anxiety-like Behavior in Mice

[0023] Figure 1The performance of mice in the open field test is depicted. Compared with the control group, the model group significantly reduced the time spent in the central area and the number of times entering the central area, indicating that the anxiety model was successfully established. At the same time, different doses of chrysanthemum charcoal administration groups effectively increased the tendency of mice to explore and stay in the open central area.

[0024] Figure 2 The movement of mice in the elevated plus maze experiment is depicted. Compared with the control group, the model group spent significantly less time in the open arm and the proportion of times it entered the open arm, indicating that its activity area was significantly smaller and mainly confined to the closed arm, indicating that the anxiety model was successfully established. In contrast, the groups administered with different doses of chrysanthemum charcoal expanded their range of activity and entered the open arm more widely. Both behavioral tests reflected that chrysanthemum charcoal has the ability to improve anxiety-like behavior.

[0025] 4. Effects of chrysanthemum charcoal on neurotransmitters and hormone levels of hypothalamus-pituitary-adrenal axis in anxious mice

[0026] Studies have shown that neurotransmitters and hypothalamus-pituitary-adrenal axis hormone levels play a very important role in the occurrence and development of anxiety. Combined with previous related studies, CRH, ACTH, CORT, Glu, GABA, 5-HT, DA, and GABA were selected for testing. Figure 3 The results showed that the levels of HPA axis hormones in the serum of pretreated mice were significantly reduced; the levels of 5-HT and GABA in brain tissue increased, and the level of Glu decreased. Among all the doses, the high dose of chrysanthemum charcoal had the best effect.

Claims

1. Use of chrysanthemum charcoal in preparing a composition for treating anxiety.

2. The use according to claim 1, characterized in that The composition is any one of a medicine, a health product, and a food, and the composition can be prepared into a clinically acceptable oral preparation; further preferably, the clinically acceptable oral preparation is one or more of a pill, a capsule, a tablet, a granule or a liquid oral preparation; more preferably, the oral preparation is a granule.

3. The use according to claim 1, characterized in that The composition may or may not contain pharmaceutically acceptable excipients.

4. The use according to claim 1, characterized in that Use with other drugs or alone.

Images